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Renal injury induced by brain death is characterized by
ischemia and inflammation, and limiting it is a therapeutic
goal that could improve outcomes in kidney transplantation.
Brain death resulted in decreased circulating nitrite levels
and increased infiltrating inflammatory cell infiltration into
the kidney. Since nitrite stimulates nitric oxide signaling in
ischemic tissues, we tested whether nitrite therapy was
beneficial in a rat model of brain death followed by kidney
transplantation. Nitrite, administered over 2h of brain death,
blunted the increased inflammation without affecting brain
death–induced alterations in hemodynamics. Kidneys were
transplanted after 2 h of brain death and renal function
followed over 7 days. Allografts collected from nitrite-treated
brain-dead rats showed significant improvement in function
over the first 2 to 4 days after transplantation compared with
untreated brain-dead animals. Gene microarray analysis after
2h of brain death without or with nitrite therapy showed
that the latter significantly altered the expression of about
400 genes. Ingenuity Pathway Analysis indicated that
multiple signaling pathways were affected by nitrite,
including those related to hypoxia, transcription, and genes
related to humoral immune responses. Thus, nitrite therapy
attenuates brain death–induced renal injury by regulating
responses to ischemia and inflammation, ultimately leading
to better post-transplant kidney function.
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Brain-dead (BD) donors account for a significant source
(B60%) for all renal allografts transplanted in the United
States. Kidneys acquired from BD donors have inferior
survival rates compared with living donors because of brain
death–induced organ injury that comprises initially of
massive acute cerebral injury, neurogenic shock, systemic
vasoconstriction, and hypoperfusion of multiple organs
including the kidney.1–4 In addition to the tissue ischemia
that ensues, electrolyte abnormalities and increased levels of
pro-inflammatory cytokines after brain death combine to
result in inflammatory injury to the kidney, which primes
this organ for an exacerbation of ischemia–reperfusion (I/R)
injury response after transplantation.5,6 This ‘two-hit’
process is a major contributor to poor kidney function
and allograft survival after transplantation using organs
from BD donors and has been demonstrated with other
organ transplants. Limiting ischemic and inflammatory
injury by treating the BD donor with corticosteroids,
recombinant soluble P-selectin glycoprotein ligand, or
erythropoietin has been shown to improve post-transplanta-
tion renal function and survival in experimental models,
supporting the idea that therapeutics targeting the BD phase
can be beneficial.7–9
Nitric oxide (NO) is an important endogenous mod-
ulator of inflammation, and at lower concentrations it
protects against inflammatory stress by multiple mecha-
nisms including limiting leukocyte adhesion, antioxidant
activity, improving tissue oxygenation, and inhibiting cell
death. This view is supported by studies showing that
therapies that increase NO bioavailability confer protection
against I/R injury in both experimental and clinical
studies.10–17 Major limitations with NO therapy are
unwanted systemic vasodilator effects, highlighting the lack
of therapies that target NO formation to specific tissues.
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Inorganic nitrite (NO2
) has long been considered an inert
end product of aerobic NO metabolism. However, recent
insights reveal the presence of biological mechanisms that
result in the 1-electron reduction of nitrite back to NO and
stimulation of NO-dependent signaling. Importantly, this
reduction is focused in hypoxic (or ischemic)/acidic tissues
resulting in targeted NO formation. Proposed biochemical
mechanisms include nitrite reduction by heme/molybde-
num-containing metalloproteins (including xanthine oxi-
doreductase, hemoglobin, and myoglobin), whose ability to
reduce nitrite is dependent on lower oxygen tensions.18–22
Consistent with this concept, several studies have shown the
potential for nitrite therapy to stimulate NO signaling only
in ischemic tissues and mitigation of I/R injury.11,13,23–28
Moreover, there is precedent for NO-based therapy to
counter the detrimental effects of brain death. L-arginine
therapy repletes NO signaling and protects against brain
death–dependent endothelial dysfunction and myocardial
blood flow.29
In this study, we evaluated the potential of nitrite to pro-
tect against I/R damage that occurs to the kidney during
brain death and improve function after transplantation.
Presented data show that nitrite therapy to the BD donor can
be administered safely and can improve function after
transplantation via anti-inflammatory mechanisms.
RESULTS
Brain death (2 h) decreases circulating, but not renal,
nitrite levels
Nitrite levels decrease during ischemic stress and nitrite
therapy has been shown to improve renal function after
I/R.13,25,28,30 Using nitriteþ nitrate as an index for NO pro-
duction, previous studies have concluded that excessive NO
formation does not occur during 2 h of brain death in rats.31
Recent studies, however, have suggested that nitrite is a more
selective index of NO formation in mammals.32 Figure 1 shows
that circulating nitrite levels are decreased B60–70% after 2 h
of brain death. However, renal nitrite levels did not change
after brain death.
Hemodynamic effects of nitrite therapy during brain death
During induction of brain death in this model, mean
arterial pressure (MAP) increases and then rapidly (within
10min) decreases and remains lower than that before brain
death (Figure 2). Nitrite is a vasodilator and can promote
hypotension. Initial studies were therefore designed to
determine the optimal conditions for nitrite administration
that would not exacerbate hypotension during brain death.
Bolus administration of nitrite (0.1mg/kg) led to a lower
MAP compared with brain death alone (not shown). We
therefore tested an alternative nitrite administration protocol
in which nitrite (0.1mg) was administered over 2 h of brain
death. Figure 2 shows that using this protocol nitrite did not
alter MAP compared with brain death alone and was tested
further for potential protective effects against brain death–-
induced kidney injury.
Nitrite therapy improves post-transplantation function of
kidneys after brain death
Kidneys from rats rendered BD for 2 h, which were
administered either saline or nitrite, were transplanted and
renal function assessed by measuring plasma creatinine andP
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Figure 1 |Circulating nitrite levels are decreased during brain
death (BD). (a) Plasma, (b) red blood cell (RBC), and (c) kidney
concentrations of nitrite were measured in rats after 2 h of
sham (control), BD, or BDþ nitrite therapy. Data show
means±s.e.m., n¼ 3–5. *Po0.05, **Po0.02 relative to control
by t-test. NS, not significant. (d) Time-dependent changes in
plasma nitrite levels in BD and BD±nitrite therapy groups. Data
show fold change relative to time 0 (before BD induction) and are
mean±s.e.m. (n¼ 2–3). Po0.01 by two-way analysis of variance
(ANOVA) and *Po0.01 by Bonferroni post test. Plasma nitrite
levels without normalization to protein ranged between 44 and
1140 nM.
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Figure 2 | Effects of nitrite therapy on mean arterial pressure
(MAP) during brain death (BD). Rats were rendered brain dead
(-K-) and then administered nitrite (0.1mg/kg) over 2 h (-&-).
No significant difference between BD alone or BDþ nitrite
administered over 2 h by two-way repeated measures analysis
of variance (RM ANOVA) was observed. Data show mean±s.e.m.
(n¼ 5) for BD alone or BDþ continuous infusion of nitrite.
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blood urea nitrogen (BUN) as a function of time after
transplantation. Figure 3 shows that after transplantation
of a kidney after brain death, plasma creatinine and BUN
increased for 2–3 days and then started to decrease, indicating
an initial worsening of renal function followed by resolution
of injury. After transplantation of kidneys isolated from BD
rats treated with nitrite, however, creatinine and BUN levels
were lower and decreased at a faster rate compared with the
BD-alone group. Figures 1a–c shows that the protective
effects of nitrite occurred without significant increased nitrite
levels in the plasma, red blood cells, or kidneys 2 h after brain
death induction. However, Figure 1d shows that although
circulating nitrite levels decrease from the onset of brain
death alone, with nitrite therapy plasma nitrite levels are
elevated for the initial 30–60min and then gradually decrease
over the next 60min.
Nitrite prevents brain death–induced inflammation in the
kidney but not lipid peroxidation
To evaluate the mechanisms underlying improved renal
function after transplantation of kidneys collected from
nitrite-treated BD rats, expression of several markers/mediators
of inflammation and oxidative stress were measured in kidneys
collected after 2 h of brain death. Figure 4 shows representative
immunofluorescence staining for the adhesion molecules
CD11a, CD11b, CD18, and the protein adduct of 3-hydroxy
nonenal. All these markers increased after 2 h of brain death
and showed a tubular location consistent with increased
inflammation and oxidative stress. Nitrite treatment decreased
staining for CD11a and CD11b, which was further confirmed
by a significant decrease in CD11b measured by western blotting
(Figure 4b). Interestingly, nitrite did not affect 3-hydroxy
nonenal staining. No changes in the expression of the pro-
inflammatory peroxidase myeloperoxidase, the inflammatory
marker 3-nitrotyrosine, or adhesion molecules intercellular
adhesion molecule-1 and vascular cell adhesion molecule-1
were observed in BD-exposed rats (not shown).
Effect of 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-
l-oxyl-3-oxide (C-PTIO) and allopurinol on nitrite-dependent
protection against renal inflammation
Previous studies have shown that NO scavenging (by C-PTIO)
and/or inhibition of nitrite reduction to NO by xanthine
oxidoreductase (using allopurinol) prevents nitrite-depen-
dent protection against ischemic tissue toxicity. Using CD11b
expression as a marker, C-PTIO had no effect on brain
death–induced renal injury and did not significantly reverse
the protective effects of nitrite, although a trend toward a
reversal is noted (Figure 4b). Allopurinol itself protected
against brain death–induced renal inflammation. Nitrite had
no additional effects and allopurinol did not reverse nitrite-
dependent inhibition of CD11b expression (Figure 4b).
Nitrite-dependent changes in gene expression determined by
microarray profiling
Supplementary Figure S1A online shows a heat map showing
that nitrite therapy altered the expression of 381 genes relative
to brain death alone, with 264 being downregulated and 117
upregulated. Ingenuity Pathway Analysis (IPA) generated 19
networks (with 41 focus molecule identified) affected by
nitrite therapy (Table 1), and was consistent with recent
reports showing that nitrite therapy has diverse effects on
gene expression profiles.33 Interestingly, the highest ranked
network was related to the humoral immune response, an
established key element of inflammatory tissue injury during
brain death in the kidney.34 Supplementary Figure S2 online
illustrates the top five canonical signaling pathways that are
most significantly affected by nitrite therapy (elF2, Notch,
HIF1a, Nrf2/oxidative stress, and elF4/p70S6K, respectively)
and also indicates specific genes that may be modulated by
nitrite therapy. Supplementary Figure S1B online lists the
number of genes that are downregulated or upregulated
within these pathways. Figure 5 shows real-time PCR analyses
of nine selected genes encompassing the top five pathways and
separates these into those that either did not change or were
upregulated by nitrite plus brain death relative to brain
death alone. Supplementary Table S1 online compares mRNA
array data with real-time PCR data and shows that nitrite-
dependent changes indicated by mRNA arrays were validated
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Figure 3 |Nitrite treatment improves post-transplantation
renal function after brain death (BD). Kidneys were isolated
from brain-dead rats treated with saline (-K-) or nitrite (-’-) and
then transplanted. Data show (a) serum creatinine and (b) blood
urea nitrogen (BUN) levels in the recipient as a function of time
after transplantation. Data are means±s.e.m. (n¼ 6) and are
significantly different (Po0.0001 for creatinine and Po0.005 for
BUN) by two-way analysis of variance (ANOVA) and *Po0.001 or
#Po0.05 by Bonferroni post test relative to BDþ nitrite.
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with four of the selected genes. Finally, as one of the genes
validated to increase with nitrite therapy was Keap1, relative
expression of Nrf2 was also determined. Figure 5 shows that
this was increased as well with nitrite therapy relative to brain
death alone.
DISCUSSION
BD donors comprise a significant resource of kidney
allografts for transplantation. A major limitation of organs
collected from BD donors is the enhanced sensitivity of the
organ to injury after transplantation when compared with
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Figure 4 |Nitrite treatment prevents brain death (BD)–induced increases in markers of leukocyte infiltration but not oxidative
stress. (a) Representative immunofluorescence images for Cd11a, Cd11b, Cd18, and 3-HNE (red staining) in control, BD (2 h), or BD
(2 h)þ nitrite groups. Blue staining represents nuclei stained with Hoechst 33342. (b) Western blot analysis for expression of CD11b/b-actin
ratios. Data show mean±s.e.m. (n¼ 2–6) and are normalized to the BD-alone group (set at 100%). Po0.001 by one-way analysis of
variance (ANOVA) with *Po0.05 relative to sham, **Po0.05 relative to BD alone, #Po0.01 relative to BD alone by Tukey’s multiple
comparison post test. C-PTIO, 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-l-oxyl-3-oxide; 3-HNE, 3-hydroxy nonenal.
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Table 1 | Signaling networks and components affected by nitrite therapy as identified by Ingenuity Pathway Analysis (IPA)
ID Molecules in network Score
Focus
molecules Top functions
1 kADAM17, mANXA13, Cbp, mCOPS2, mCOPS3, mDUSP5, mECSIT, mHLA-C, mHLA-G,
IFN-a/b, IFN-b, mIRF3, mLITAF, mLRRFIP1, mLY6C1, MHC Class I (complex), MHC
CLASS I (family), NF-kB (complex), mNLRC4, Notch, mNUP98, kNUPL1, mPAK1IP1,
kPDIA3, kPNPT1, mPTMA, mS100A6, mSEC13, mSLC2A5, sphingomyelinase,
mSUGT1, Tap, kTFG, kTFPI, mZMYND11
43 26 Antigen presentation, antimicrobial
response, humoral immune response
2 Akt, Ap1, mAPEX1, mASCC2, kASS1, Ck2, mCPT1B, Cyclin A, kDARS, mDGCR6,
mDHRSX, kDNMT1, kEED, mEEF1D, mEGLN2, Estrogen receptor, mHBB (includes
EG:3043), kJUN, mKLF7, kM6PR, kNFKBIB, oxidoreductase, mPDCD2, peptidase,
mPI4KA, mPIP4K2A, kPSAP, Rar, kRORA, Rxr, mSLC19A1, kSNW1, mTHRB, Thyroid
hormone receptor, mVARS
42 25 Gene expression, tissue morphology,
amino acid metabolism
3 a-Tubulin, mBNIP3L, mCCT5, Creb, mDCN, mDUSP3, mEIF2B4, ERK1/2, FSH, kGEM,
Gsk3, mGSK3B, mHSPA14, Insulin, mKLC1, Lh, mMAP4, p70 S6k, mPAF1, kPAH, PDGF
BB, mPDPK1, Pi3-kinase, kPOLR2B, PP1 protein complex group, PP2A, Ppp2c,
mPPP2R2D, kRBBP5, mROCK2, Rsk, mSLC6A6, mSTIP1, kSTK16, mTXK
33 21 Cell morphology, reproductive system
development and function,
developmental disorder
4 mC4ORF27, CDC5L, mCOMMD9, mCOQ6, mGLTSCR2, HNF1A, HNF4A, ITGB3BP,
kKIAA1012, mMRPL15, mMRPL22, mMRPS11, kMRPS14, kMTHFS, POLRMT, mPRCC,
SFRS2, kSLC35A3, mTFB2M, TGFB1, mTMEM140*, mTTC22, mZNF410
27 16 Gene expression, tissue development,
endocrine system development and
function
5 Alp, a-catenin, mATF4, Caspase, mCOL4A3, Collagen type I, Collagen type IV,
mDDX31, mDDX52, mEDNRB, mHBXIP, kHES1, Holo RNA polymerase II, Hsp70, IL1,
IL12 (complex), Immunoglobulin, Jnk, LDL, mMED29, kMED30, Mmp, kNCSTN,
kNME3, mNOP58, PI3K, mPSEN1, mPTGES, RNA polymerase II, mTAF8, mTARDBP,
mTCEB1, Tgf-b, kTMED2, Vegf
26 18 Nervous system development and
function, organ development,
embryonic development
6 ABCD3, mAP3B1, mBAT1, mBLOC1S1, BNIP1, mEMG1, mHDDC3, HNF4A, LSM3,
mLSM4, LSM5, kLUC7L2, mMRPL43, NAPA, NMI, NSF, mPELO, mPOLD4, POLE, POLL,
mPPP6C, RFC3, SART3, SEC22B, mSFRS11, mSLC25A38, SOX10, mSTK19, STX18,
SUPT7L, TADA1, mTEAD3, mTMEM87B, mUSE1, ZSCAN16
25 17 Cellular assembly and organization,
molecular transport, protein trafficking
7 mB3GNT1, mBANP, mBMPR2, Calcineurin protein(s), Cdc2, mEPS8, mEPS8L2, ERK, F
Actin, mFLNB, Focal adhesion kinase, mHABP4, hCG, Ige, kIRX1, kJUNB, kLUC7L2,
mMAP3K4, mMAPK14, mMAPKAPK2, Nfat (family), NGF, mNOP56, P38 MAPK, Pdgf,
Pka, Pkc(s), mPLCG1, Rac, Ras, mRPA2, mRYR1, Sapk, TCR, VAV
21 17 Cell morphology, cellular assembly and
organization, genetic disorder
8 kC10ORF2, DBN1, DDX56, mEG623169, EIF4A2, glutamyl-Se-methylselenocysteine,
JRK, mLOC440733, LONP1, LYAR, MAGEB2, mMRPL23, MT-ND4, MT-ND5, MT-ND6,
MT-ND4L, mMYO1C, mNDUFA10 (includes EG:678759), NDUFV2, PA2G4, kPGCP,
phosphatidylinositol-3-phosphate, PIN4, PINX1, mRPL24, mRPL10A (includes
EG:19896), mRPL13A, mRPL18A, mRPS11, selenomethylselenocysteine, SLC2A4,
SNX1, mTXNDC12, mWDFY1*, WDR8 (includes EG:49856)
19 14 Cancer, genetic disorder, neurological
disease
9 ANAPC13, mBAT1, kC16ORF80, mCDC16, CDC27, mDNAJC11, mDPEP1, DUSP15,
EXTL3, mFAM110A, mFNBP4, FYN, GRB2, HTT, ISG20L2, kLUC7L2, MEPE, mOSBPL3,
PAX3, mPDE10A, POP1, POP4, mRBM25 (includes EG:58517), RIN3, mRPP14, RPP21,
RPP30, RPP38, RPP40, mRPS13, SAPS3, SUV39H2, SVIL, mTMEM102, YWHAG
19 14 Nervous system development and
function, organismal development,
neurological disease
10 AHSG, ANAPC2, ANAPC4, mATOX1, BACE1, BMP1, mDAZAP1, mDCN, EIF4E,
mENTPD5, Eotaxin, Ferritin, FN1, mGNL1, mHCCS, Ifn, ITGB6, LGALS3BP, NAIP,
mPAPPA, mPDRG1, PGF, PRG2, mPTMA, mSGCA, mSNRPA, SOCS, SOCS3, kST6GAL1,
STX6, SVIL, Talin, TNF, mVPS45, XIAP
17 13 Inflammatory disease, skeletal and
muscular disorders, cellular response to
therapeutics
11 kAASS, mACVR2B, AHNAK, mBANP, BUB1, CDH13, CDKN1A, mCNIH4, mCNKSR3,
COL6A1, COL6A3, DHX36, ERBB2, mFAM110B, mGALNT3, kGOLGA5, IARS, ILK, LXN,
mMAP4, MSTN, NET1, kPANK2, PARVA, RAB1A, Rb, mRFC4, RRAD, mS100A6, SPINT2,
TGFB1, Type II Receptor, VPS39, YWHAZ, mZNF593
17 13 Genetic disorder, skeletal and muscular
disorders, skeletal and muscular system
development and function
12 ATXN1, b-estradiol, mC13ORF33, mCDK11A, EDA, EIF3, EIF3B, EIF3CL, mEIF3D, EIF3G,
mEIF3H, EIF3K, EIF3L, kEIF4G3, GAR1, GARS, GMFB, kKIAA2026, MBP, NARS, mNHP2,
PNP, PTPRD, mPYGM, kR3HDM2, RCN2, RHPN2, mSAMD8, SAPS2, mSPOCK2,
TGFBR1, TRAF6, VAMP1, kVAPA, mWFDC2
17 13 Protein synthesis, digestive system
development and function, cell death
13 ASCC3, kAUH, BATF, mC21ORF7, C3AR1, kC9ORF46, mCD248, CD3EAP, COL6A3,
CYSLTR2, mDUSP11, GPX4, mHDLBP, IL4, IL13, IL15, IL19, mLAS1L, LGALS3BP, LSP1,
MIR373, kMKRN1, kMRPS10, RELA, RETNLA, kRNF25, SFRS7, kSLC25A23, SPINT2,
SPRR1A, mST7, kSYAP1, TMEM9B, TNFSF4, XRCC6
17 13 Cellular growth and proliferation, tissue
development, cell-to-cell signaling and
interaction
14 mDUSP5, FKBP1A, FKBP1B, GATA3, kGOLGA7, HRAS, IL5, mKCTD9, KLF3, MIR302A
(includes EG:407028), kMYADM, peptidylprolyl isomerase, PIN4, PPIB, PPID, PPIF,
mPPIL3, mRPS10, mSCYL1, SERPIND1, mSLU7, SRF, mST7, TIMM10, TIMM17B,
mTIMM8B, TOMM6, TOMM7, TOMM20L (includes EG:75266), TOMM40L, TOMM5
(includes EG:68512), kUPB1, kZC3H8, ZDHHC9, mZNF207
17 13 Post-translational modification, protein
folding, cancer
15 mACE2, AMPK, kANGEL1, CHAF1A, CXCL1, mDCN, mDDX24, DPM2, DUSP1,
mHDAC1L, HEXIM1, IL6, KIF11, MAP3K1, kMLF2, NOP2, phosphatidylinositol N-
acetylglucosaminyltransferase, PIGA, PIGB, PIGC, kPIGH, PIGP, PIGQ, PIGY, RNase A,
17 13 Tumor morphology, cellular
development, hematological system
development and function
Table 1 Continued on the following page
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organs collected from living donors. This is important
because the extent of this injury is inversely related to organ
function and graft viability and provides a target for
therapeutic intervention to both limit brain death–induced
injury and prevent secondary transplantation–induced renal
dysfunction. Underlying brain death–induced injury is
increased ischemia and inflammation. Recent studies have
shown that rather than an inert metabolite of aerobic NO
metabolism, at low concentrations (nM/mM), nitrite can serve
as a source for NO specifically under hypoxic and/or acidic
conditions. This concept has been demonstrated by (1)
decreased nitrite levels during ischemic stress, with the
concomitant increase in NO and NO–protein adducts;13,35–38
(2) stimulation of NO signaling in hypoxic, but not
normoxic, tissues;24,39 and (3) nitrite therapy protecting
against I/R injury in diverse organs systems by NO
formation.11–13,21,40,41 This, together with decreased circulat-
ing nitrite levels during brain death (Figure 1), consistent
Table 1 | Continued
ID Molecules in network Score
Focus
molecules Top functions
mRPL10A (includes EG:4736), kSALL1, mSP110, SPTAN1, TMEM9B, kTSSC4, VEGFA,
kYIPF4, ZFP36, mZNF692
16 APH1A (includes EG:51107), APH1B, kBCAS2, CAPN1, CCAR1, COMT, DDIT4, kECHS1,
kEI24, GLUL, kJMJD8, JMJD1C, LIG3, MIR34A (includes EG:407040), mNLRC4, NR3C1,
PARP, kPARP2, kPARP4, mPHF17, mPLEKHF1, PSENEN, mRBBP6 (includes EG:5930),
kSCAMP1, SNCAIP, SUPT16H, TEP1, TP53, TPT1 (includes EG:7178), Ube3, mUFC1,
kUFSP2, VHL, XRCC1
16 13 Post-translational modification, cell
death, small molecule biochemistry
17 ACTR6, AGT, AGTR1B, ARPC5, FOLR2, FOS, GNAO1, Immunoproteasome Pa28/20s,
mLOC119358*, MOS, mMSLN, POMP, kPRELID1, Proteasome PA700/20s, PSMA,
PSMA1, PSMA4, PSMA5, mPSMA7, PSMB2, PSMB3, PSMB4, mPSMB6, mPUS1, RARB,
mRGS11, RPL7A (includes EG:6130), mSLC4A3, SNCG, STAT6, TOM1, mTWISTNB,
mUBA52, mZFAND2A
13 11 Drug metabolism, molecular transport,
small molecule biochemistry
18 ABCD3, ACTC1, AFG3L1, ATP5B, ATP6V0B, mATP6V1G2, ATPase, mBAT1, mC20ORF7,
kCHMP7, mCHMP2A, CHMP4A, CHMP4B, CHMP4C, mCSAD, DDX1, DDX39, DNAJC14,
ESCRT3, ESRRA, HLTF, MIRN324, MT-ATP8, MYH1, MYO9A, PPP2R4, RECQL5, RFC3,
mSARNP, SKIV2L, kSTAMBP, mTHOC2, VPS24, VPS4B, kZC3H4
12 10 Molecular transport, DNA replication,
recombination, and repair, energy
production
19 26s Proteasome, Actin, ATXN3, DNAJB2 (includes EG:3300), mGM10117, H2-LD,
Histone h3, kHNRNPK, Hsp90, ID3, IKK (complex), Interferon-a, kKEAP1, Mapk,
MAPK6, MOS, mMYH14, NEB, PACRG, PLA2G6, mPPAN-P2RY11, RAB8B, mROCK2,
RPS3, SNCAIP, mTES, mTMCO6, Tropomyosin, TRPM7, Ubiquitin, UBQLN1, USP2,
mUSP3, USP18
10 9 Cellular assembly and organization, cell
cycle, cellular movement
Genes indicated in bold with either an up or down arrow were those found in data set. Genes in normal font are genes that IPA used to connect the genes together within
networks. * Denotes genes found in 41 network.
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Figure 5 | Effects of nitrite on brain death (BD; 2 h)–induced changes in gene expression in the kidney. Real-time PCR analyses of
indicated genes were performed. Data show fold change relative to BD alone and are mean±s.e.m., n¼ 3. For all upregulated genes,
Po0.05 by t-test.
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with ischemic stress, provided the rationale for testing nitrite
therapy to attenuate brain death–induced renal injury and
improve function after transplantation.
Decreased circulating nitrite levels could be due to
endothelial dysfunction, as previously reported with brain
death,29 and/or increased consumption, which has also been
reported in the setting of ischemic tissue injury.13 In fact,
data showing that nitrite levels in the circulation rise and
then fall despite continual administration over 2 h of brain
death (Figure 1d) suggest that increased nitrite consumption
is occurring. Renal nitrite levels did not change with brain
death, suggesting that with the relatively mild (only 2 h of
brain death) model used herein ischemic stress in the circu-
lation is more prevalent. Further studies evaluating nitrite
therapy using longer BD times that also more severely com-
promise organ function are clearly required.
Most previous studies have shown nitrite protection against
IR injury to be mediated by NO formation. In this model,
nitrite targets NO formation only in the ischemic tissue, where
it can stimulate multiple signaling responses that result in
inhibition of IR injury, including attenuating inflammation
and oxidative stress, inhibiting cell death, promoting blood
flow, and regulating mitochondrial respiration.20,40 Impor-
tantly, all of these potential effects could have a role in the
observed protective effects of nitrite during brain death. On
the basis of the fact that brain death causes decreased nitrite
only in the intravascular compartment, we posit that the
protective effects of nitrite are mediated primarily in the
circulation and perhaps by improving renal blood flow or
attenuating leukocyte activation, which could explain de-
creased CD11a and CD11b levels in the kidney. Coadminis-
tration of C-PTIO did not reverse nitrite-dependent
protection, suggesting that NO-independent mechanisms are
operating to limit kidney injury. In addition, a role for
xanthine oxidoreductase was difficult to assess as allopurinol
itself prevented brain death–induced injury more so than
nitrite, suggesting that increased reactive oxygen species
production has a role in brain death–induced organ dysfunc-
tion, a conclusion supported by increased lipid peroxidation
in the kidney (Figure 4a).
Despite the lack of understanding of where nitrite is
exerting protective effects, it is clear that nitrite therapy affects
gene expression profile in the kidney after brain death.
Previous studies have shown changes in the expression of
60–90 genes using microarray analysis in kidneys 6 h after
brain death.34 Interestingly, differential profiles of genes being
upregulated or downregulated are observed in the kidney after
brain death, and encompassed genes that affected metabo-
lism/transport, immune/inflammatory cell activation, growth/
fibrosis, and defense/repair processes. We used gene arrays to
gain insights into potential mechanisms by which nitrite
protected against brain death–dependent renal injury and
specifically those that are not revealed by analysis of candidate
markers of inflammation and oxidative stress. IPA of networks
affected by nitrite compared with brain death alone showed
that many processes were potentially affected (Table 1),
including gene expression and modulation of humoral
immune response, the latter being consistent with nitrite
inhibiting inflammatory stress.
Within the top five canonical pathways that were most
significantly affected by nitrite therapy, only a small percentage
of total genes were in fact modulated by nitrite (4–10%),
suggesting a specificity of responses. Real-time PCR analysis
was performed on selected genes encompassing these path-
ways. Supplementary Table S1 online shows B50% con-
cordance between changes in gene expression mediated by
nitrite determined by array and real-time PCR analysis.
Importantly, however, at least one gene from each of the top
five pathways identified as changing in response to nitrite
therapy was validated by real-time PCR (Figure 5). Two of the
top five pathways relate to expression of eukaryotic initiation
factors with nitrite therapy upregulating eIF4g. The exact
consequences of such changes are difficult to predict, but are
consistent with high diversity of genes affected by nitrite,33 as
indicated in Table 1. The second pathway was related to Notch
signaling, an increase of which has recently been shown to
facilitate tubular repair after acute renal injury.42 Nitrite
therapy increased the expression of g-secretase, suggesting that
increased Notch cleavage and subsequent stimulation gene
transcription will occur. Potential effects of nitrite on HIF1a
and Nrf2 (pathways 3 and 4, respectively) are clearly of interest
with respect to known mechanisms of brain death–induced
renal injury. Interestingly, nitrite therapy upregulated elongin-
C; the predicted consequence is limited activation of HIF1a
and may represent an affect of nitrite in countering brain
death–induced ischemic stress. One potential mechanism is
possible improvement in renal blood flow via reactions with
hemoglobin.43,44 Moreover, nitrite therapy upregulated the
expression of Keap1 and Nrf2. Keap1 binds Nrf2 in the cytosol,
preventing the latter from inducing a variety of stress response
genes that protect cells from oxidative and inflammatory
stimuli. Although relatively little is known on how expression
levels of Keap1 and Nrf2 mRNA affect responses to oxidative/
inflammatory stimuli, these data suggest that nitrite may affect
oxidative and nitrosative signaling via these key transcription
factors. Further studies evaluating how protein levels and
transcriptional activity of the aforementioned mediators
(identified from array and real-time PCR studies) change
during brain death injury in the presence or absence of nitrite
therapy are a necessary next step to further defining mech-
anisms of nitrite protection.
The current studies evaluated nitrite therapy during brain
death itself and not after transplantation-dependent inflam-
matory injury. However, numerous studies have shown pro-
tective effects of nitrite during organ transplantation and/or
IR injury, and in most of these instances nitrite is effective
regardless of how it is administered (dietary, intraperitoneal,
intraorgan injection, or intravenous).11,13,14,28,45 With respect
to the kidney, however, the route of administration of nitrite
appears to have an important role. Intraperitoneal or
intravenous administration did not protect against renal I/R
injury,46 whereas topical administration did.25,30 The mechanistic
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basis for this difference remains unclear. However, intra-
venous nitrite administration does protect the kidney from
brain death–induced injury. How nitrite is administered
during brain death is also important when assessing safety.
A key element in brain death–induced kidney injury is hypo-
tension, as demonstrated by experimental studies showing
decreased injury when hypotension is avoided.4 Indeed,
clinically, the management of hypotension is by administra-
tion of fluid and/or vasoconstrictors. Nitrite is a vasodilator,
which raises concerns about using this anion as a therapeutic.
Initial studies testing bolus nitrite administration decreased
MAP compared with brain death alone, resulting in morta-
lity. However, administration of nitrite as for the duration of
brain death did not result in additional hypotension and did
not promote mortality. These data show that in the setting of
brain death, nitrite can be administered safely and it protects
against brain death–induced renal injury; however, the route
of administration is critical.
The limitations of this study include the lack of precise
mechanistic insights into how nitrite prevents brain death–-
induced renal injury. Moreover, we note that a relatively mild
(2 h) brain death injury model was used (the severity of brain
death injury increases with increased time of brain death4).
Despite these limitations, the data presented herein support
the feasibility of NO-based and specifically nitrite-based
therapy for limiting brain death–induced renal injury.
In summary, we have shown that nitrite can be
administered safely in a rat brain death model and was able
to mitigate the brain death–induced I/R injury to renal grafts
and improve post-transplant renal function. Nitrite admin-
istration during 2 h of brain death resulted in decreased
markers of infiltrating inflammatory cells in the kidney, and,
more importantly, resulted in kidneys whose function was
significantly improved after transplantation compared with
an allograft obtained from a BD-alone rat. These data suggest
that nitrite prevents ischemic/inflammatory tissue injury
during the BD phase, which results in a kidney that is more
resistant to subsequent IR injury after transplantation.
Whether nitrite-dependent protection occurs by affecting
inflammation, tissue perfusion, or the kidney responses to
ischemic and inflammatory stress is not clear. Gene array
studies clearly suggest, however, that modulation of renal
responses to stress is likely to have a role.
MATERIALS AND METHODS
Animals
Male Lewis rats aged 8–12 weeks and weighing 250–300 g were used.
Animals were fed a normal NaCl diet (AIN-76A) (Dyets, Bethlehem,
PA) as previously described47 and allowed free access to water. All
procedures were approved by the institutional animal care and use
committee at the University of Alabama at Birmingham.
Brain dead model
Brain death was induced by balloon inflation of a Fogarty catheter
introduced into the subdural space through an occipital burr hole as
described in detail in Supplementary Material online. Briefly, after
anesthesia, rats were intubated and mechanically ventilated with
intermittent positive pressure for 2 h. Arterial blood pressure was
monitored continuously. All animals received 0.9ml of lactated
Ringer solution intravenously for 30min during the 2-h period. A
1-mm hole was drilled through the skull 0.3 cm lateral to the sagittal
suture, and then a No. 3 Fogarty catheter was inserted through the
burr hole. For raising the intracranial pressure gradually, the balloon
was inflated with 40 ml/min saline until respiration ceased. The
absence of reflexes, apnea, and maximally dilated and fixed pupils
confirmed the condition. The balloon was kept inflated during the
entire 2-h follow-up, after which left and right kidneys were
harvested. Left kidney was used for transplantation and right kidney
for mRNA or tissue collection for subsequent analyses. MAP was
controlled and maintained between 60 and 80mmHg by addition of
lactated ringers solution and Hespan as necessary. We note that with
bolus administration of nitrite fluid administration was not able to
increase MAP (see Figure 2).
Nitrite therapy
Sodium nitrite (Sigma, St Louis, MO) was dissolved in sterile
phosphate-buffered saline and administered intravenously either as
a bolus injection (0.1mg/kg, in a 100ml volume) or by injecting
133 ml every 10min (over 2 h, the first dose starting 10min after
induction of brain death), resulting in 0.0083mg/kg/injection or
0.1mg/kg over 2 h. Saline was used as a control for nitrite. Nitrite
administration was started 10min after brain death induction.
C-PTIO and allopurinol were administered at 1mg/kg after
induction of brain death.
Kidney transplant
Kidney transplantation surgery (Lewis to Lewis syngeneic transplanta-
tion) was performed according to the method previously described,48
and is also described in detail in Supplementary Material online.
Creatinine and BUN assay
Serum creatinine and BUN levels were assayed using a VetACE
biochemistry machine (Alfa Wasserman, West Caldwell, NJ).
Histology and immunofluorescence
Paraffin-embedded kidney sections were deparaffinized and stained
with the indicated antibodies as described in Supplementary Material
online.
Western blotting
Western blotting was performed as described in Supplementary
Material online.
Nitrite measurements
Nitrite was measured in the blood and kidneys as previously
described and in Supplementary Material online.16
RNA isolation for gene analysis
Detailed methods are provided in Supplementary Information
online. Briefly, kidneys were cut into 3 3 cm segments and flash-
frozen in liquid N2. Total RNA was then isolated using a protocol
based on the interaction of phenol and guanidine with cellular
components. Gene expression analysis was performed using the Rat
Ref-12 BeadChip and iScan system from Illumina (San Diego, CA).
The Rat Ref-12 BeadChips contain sequences representingB22,000
curated and putative genes and expressed sequence tags. Quality
standards for hybridization, labeling, staining, background signal,
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and basal level of housekeeping gene expression for each chip were
verified. After scanning the probe array, the resulting image was
analyzed using the GenomeStudio software (Illumina). Samples
were normalized using a quantile procedure, and differential gene
expression for control and treatment groups was performed via a
custom Illumina analysis designed to eliminate background noise
from the analysis by subtracting out the signal from negative beads
(Po0.05). Gene lists were not adjusted for multiple testing.
Ingenuity Pathway Analysis
The data set was analyzed by using the IPA software (version 8.7:
Ingenuity Systems, www.ingenuity.com). The data set contained gene
identifiers and corresponding expression values and was uploaded
into the application. Each identifier was mapped to its corresponding
object in the Knowledge Base of Ingenuity. Fold change for the target
molecules was used to display the genes whose expression was
upregulated or downregulated. These Network Eligible Molecules
were overlaid onto a global molecular network developed from
information contained in the Knowledge Base of Ingenuity. Networks
of Network Eligible Molecules were then algorithmically generated
based on their connectivity. The Functional Analysis identified the
biological functions that were most significant to the data set. Right-
tailed Fisher’s exact test was used to calculate a P-value determining
the probability that each biological function assigned to that data set is
due to chance alone. Canonical pathway analysis identified the
pathways from the IPA library of canonical pathways that were most
significant to the data set. The significance of the association between
the data set and the canonical pathway was measured in two ways.
(1) A ratio of the number of molecules from the data set that map to
the pathway divided by the total number of molecules that map to the
canonical pathway is displayed. (2) Fisher’s exact test was used to
calculate a P-value determining the probability that the association
between the genes in the data set and the canonical pathway is explained
by chance alone. Finally, we note that gene array analysis of control
vs. BD-alone, or control vs. nitrite-alone, groups revealed significant
and distinct gene expression profile changes compared with BD vs.
BDþ nitrite (not shown) groups. Our focus here was on under-
standing the therapeutic potential of nitrite, and hence we limit the
discussion to gene expression changes in BD þ nitrite vs. BD-alone
groups only.
Real time-PCR
Primer sequences and real-time PCR analyses were performed as
described in Supplementary Data online.
Statistical analysis
Data are presented as mean±s.e.m. The t-test was used for comparisons
between two groups. For the comparisons that involved more than two
groups, analysis of variance and the Tukey/Bonferroni post test were
used for analysis, with statistical significance considered at Po0.05.
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